ClinicalTrials.gg
RecruitingNCT06863376Updated May 4, 2026

Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

A Phase 2 interventional study of Carbocysteine 375 MG and Physical activity, walking, and calorie restriction in Non-Alcoholic Fatty Liver Disease, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Tanta University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.

Planned enrollment
10th of 12
46 · median 58
Started
2025
the only one that year
Phase 2
5 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the 10th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 11th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, or all of them as a file.
02

Study summary

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either male or female adult patients (>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or lactating women
  • Excessive alcohol use (defined as an average alcohol intake > 30 g per day in men and > 20 g per day in women)
  • Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, hepatitis.
  • patients suffering from chronic kidney disease, and hyper/hypoparathyroidism
  • to carbocistiene.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
46 participants (estimated)

Study arms

  • Active comparator
    Control group

    Patients will receive the standard conventional therapy in addition to placebo for 3 months.

    Other: Physical activity, walking, and calorie restriction

  • Active comparator
    Carbocistiene group

    Patients will be given the standard conventional therapy plus carbocistiene 375 mg two times daily.

    Drug: Carbocysteine 375 MG · Other: Physical activity, walking, and calorie restriction

Interventions

  • DrugCarbocysteineStudies of CarbocysteineCarbocysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Carbocysteine is a muco-active drug with free radical scavenging and anti-inflammatory properties. It is actually approved for clinical use as adjunctive therapy of respiratory tract disorders

  • OtherPhysical activity, walking, and calorie restriction

    • The standard conventional therapy in both groups included regular exercise in the form of any physical activity as walking, cycling, etc. for 30-45 minutes minimum 5 days per week in addition to calorie restriction in overweight and obese patients

06

What researchers measure

Primary outcomes

  1. The change in the degree of steatosis in the Ultra Sound

    The change in the degree of steatosis in the Ultra Sound

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2027, 24 months after the start.

Of 53 non-industry phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2025
First posted
Mar 7, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 20, 2027
CompletionEst.
Apr 20, 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06863376
Lead sponsor
Tanta University
Responsible party
Mostafa Bahaa (Lecturer, Tanta University) — Principal investigator
First posted
Mar 7, 2025
Start date
Mar 1, 2025
Primary completion
Mar 20, 2027 (estimated)
Completion
Apr 20, 2027 (estimated)
Last update
May 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbocysteine

Start the discussion